Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyAmeriHealth Caritas CIRS Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentAmeriHealth CaritasPolicy CCP.1371

    Chronic inflammatory response syndrome (CIRS)

    Customize your policy alerts

    Sign up for AmeriHealth Caritas Policy CCP.1371 alerts

    Get alerted when Policy CCP.1371 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy defines AmeriHealth Caritas' coverage stance on Chronic Inflammatory Response Syndrome (including dampness and mold hypersensitivity syndrome) and informs providers about coverage determinations and alternative covered services.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyChronic inflammatory response syndrome (CIRS)
    Policy CodePolicy CCP.1371
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Last ReviewJan 1, 2025
    Next Review DateMay 1, 2026
    Key ActionDocument routine patient evaluation and management by a network health care provider when providing alternative care.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Not medically necessaryCoverage stance for CIRS
    NonePolicy limitations
    AnnualReference updates
    2018Consensus referenced

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Determination

    Overall coverage stance

    Coverage determination

    CIRS coverage: Chronic inflammatory response syndrome is investigational/not clinically proven and therefore not medically necessary.

    Policy states CIRS (including dampness and mold hypersensitivity syndrome) is not medically necessary.

    Coverage for diagnoses or treatments provided specifically for Chronic Inflammatory Response Syndrome (CIRS) is excluded under this policy because the condition is considered investigational and not clinically proven.

    This policy designates CIRS as investigational and therefore not medically necessary; services aimed at diagnosing or treating CIRS do not meet AmeriHealth Caritas coverage criteria.

    Provider Requirements and Actions

    Prior Authorization

    Prior authorization — none; CIRS investigational

    No prior authorization pathway is described for services related to Chronic Inflammatory Response Syndrome (CIRS); the policy designates CIRS as investigational and not medically necessary.

    Step Therapy

    Step therapy — none specified

    The policy does not specify any step therapy requirements for diagnosis or treatment of Chronic Inflammatory Response Syndrome.

    Documentation Required

    Document routine evaluation and management for alternative services

    When alternative care is provided, document routine patient evaluation and management performed by a network health care provider.

    • Include documentation of routine evaluation and management by a network provider when submitting claims for alternative covered services.
    Denial Risk

    Denial risk — CIRS considered investigational

    Claims for diagnosis or treatment of CIRS may be denied because the policy states CIRS is investigational/not clinically proven and therefore not medically necessary.

    • Expect claim denials for services billed specifically for CIRS diagnosis or treatment.
    • Consider submitting documentation that services provided are standard E/M or other covered treatments rather than CIRS-specific interventions.

    Definitions

    Chronic inflammatory response syndrome (CIRS) — definition and description as used in the policy
    TermChronic inflammatory response syndrome (CIRS)
    Definition used in this policyA term used in some literature to describe multisystem symptoms allegedly following exposure to water-damaged buildings and biotoxins, involving proposed biomarkers (e.g., C4a, MMP9, TGF-beta-1, MSH, VIP) and symptom clusters; considered investigational/not clinically proven in this policy.
    Key proposed diagnostic featuresDocumented exposure to biotoxins, multisystem illness, distinct laboratory abnormalities (inflammatory markers and regulatory neuropeptides), and symptom clusters (e.g., at least 8 of 13 defined adult symptom clusters in the 2018 consensus).
    Proposed biomarkers referencedExamples cited in the literature include C4a, MMP9, TGF-beta-1, melanocyte stimulating hormone (MSH), and vasoactive intestinal polypeptide (VIP).
    Origins and proposed algorithmThe term and an associated testing/treatment algorithm were first described by Shoemaker (2010) for multiorgan symptoms after exposure to water-damaged buildings; the Shoemaker protocol outlines stepwise laboratory normalization and environmental exposure control steps.
    Policy appraisal of evidenceNot widely recognized in major databases (ScienceDirect, PubMed); lacks an ICD code; evidence is mainly narrative reviews, observational reports, and consensus documents rather than large randomized trials, so the condition is considered investigational by this policy.

    Background and Context

    Chronic Inflammatory Response Syndrome (CIRS) is a term used by some authors to describe a multisystem set of symptoms attributed to exposures such as water‑damaged buildings and biotoxins. The policy concludes that CIRS is investigational and not clinically proven, and thus lacks recognized coverage as a distinct, covered diagnosis.

    Policy Summary
    PayerAmeriHealth Caritas
    PolicyChronic inflammatory response syndrome (CIRS)
    Policy CodePolicy CCP.1371
    Change TypeNo material changes
    Effective DateJan 1, 2025
    Last ReviewJan 1, 2025
    Next Review DateMay 1, 2026
    Key ActionDocument routine patient evaluation and management by a network health care provider when providing alternative care.
    SourceLink
    On This Page
    Coverage DeterminationProvider Requirements and ActionsDefinitionsBackground and Context